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A NANOPARTICLE UPTAKE ASSAY TO DEMONSTRATE THE ROLE OF FC 




Director: Victor Huber, Ph.D. 
 
Vaccination against influenza can significantly minimize the severity of an 
influenza virus infection, but these vaccines are not 100% effective at preventing and 
eliminating infections. The target of vaccine-induced immunity is the hemagglutinin 
(HA) protein expressed by the virus. Antibodies that bind to the HA protein protect the 
host through neutralization, initiation of complement, or by interacting with host immune 
cells.  Virus neutralization requires high levels of antibodies, which may wane between 
vaccination and infection, antibodies that enhance host cellular responses are critical for 
maintaining anti-influenza immunity later during the season. It is known that Fc receptors 
contribute to the clearance of influenza viruses after vaccination, but the exact 
mechanism remains undefined. We have designed an uptake assay using silica 
nanoparticles to test the ability of antibodies to evaluate virus-associated 
opsonophagocytosis in macrophage cells. Pseudo virions were synthesized from silica 
nanoparticles and conjugated with a fluorescent label. HA protein was attached to the 
nanoparticles.  Using antibodies, uptake of nanoparticles was monitored using fluorescent 
microscopy.  Results show a significant difference in uptake when antibodies are used in 
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Section One: Influenza 
	
 Influenza virus infections are one of the most prevalent viral infections occurring 
at a rate of between three and five million cases per year (World Health Organization 
2018).  Influenza viruses are segmented RNA viruses that can be divided into four major 
types, A, B, C, and D, although only A and B are clinically relevant to humans (Blut 
2009).  Influenza A and B viruses have eight gene segments making up their genomes, 
and special importance is traditionally placed on the proteins located on the viral 
envelope: hemagglutinin (HA) and neuraminidase (NA).  Influenza infections can spread 
as either seasonal epidemics, which occur approximately every 2-5 years, or as less-
frequent pandemics that occur every 2-3 decades, including 1918 and 2009.  Fortunately, 
widespread influenza virus spread have been minimized by the development of 
inexpensive influenza vaccines.  
 
Section Two: Hemagglutinin 
The main target of protection in current influenza vaccines is the HA protein 
(Ohmit 11).  The HA protein is the surface protein of the influenza viral envelope that is 
responsible for binding to host cell receptors, allowing for infection (Gamblin 10).  
Antibodies that bind these HA proteins can reduce the infective potential of influenza by 
preventing the HA from binding to host cell membranes; thus blocking virus entrance 




the circulating virus strain varies from year to year.  To provide adequate protection for 
the population, annual vaccination is required to update immunity based on the current 
circulating strain and to increase the concentration of circulating antibody in the 
vaccinated individual as antibody titers wane between vaccination and the time of 
potential infection.  
 
Section Three: Correlates of Protective Immunity 
While they are available, current immunization strategies are not entirely effective 
and correlates of protection against influenza have not been completely defined.  It is 
likely that improved definition of the correlates of protective immunity will guide efforts 
toward improving the effectiveness of influenza vaccines.  Specifically, if we know the 
types of antibodies to induce through vaccination, then we can develop better approaches 
to induce these antibodies when considering influenza immunization strategies.  Today, 
assays such as the hemagglutination inhibition assay, microneutralization assay, ELISA, 
and neuraminidase inhibition assay are among the tests that are used to determine the 
protection in individuals that are vaccinated against strains of influenza (Jacobsen 2017) 
These assays, while using different techniques, detect the presence and quantity of 
antibodies in a serum sample. A vaccine is deemed protective if the assay results indicate 
that antibody concentrations are above a pre-determined antibody titer known to be 
sufficient to prevent influenza infection this is known as the correlate of protective 
immunity.  To date, an antibody titer of greater than 1:32, determined using the 
hemagglutination inhibition assay is the accepted correlate of protective immunity against 




individual, this is an imperfect correlate of protection as the titer of antibody required to 
protect an individual is likely to differ among groups of people including those in 
different age groups (Benoit 2015).  Additionally, the methods used to detect these 
antibodies focus on the portion of the antibody that binds to the antigen (Fab) without 
consideration for the portion of the antibody that interacts with host cells to direct virus 
clearance (the Fc region).  This leads to potential issues because if the host immune 
response is not properly activated, then antibody binding to the pathogen alone may not 
elicit a strong enough immune response to lead to clearance of the pathogen.  
 
Section Four: In Vivo Immune Response 
When exposed to an influenza virus HA protein, through either vaccination or 
infection, the immune system responds by generating antibodies specific to this antigen. 
The effectiveness of these antibodies is dependent on their unique conformation that 
binds to both the pathogen and the cells of the immune system.  The most common and 
important antibody in the immune response against influenza, IgG, has two distinct 
regions.  The Fab region is the region of the antibody that binds to the antigen and varies 
drastically between each different type of antibody that binds unique antigens. The Fc 
region of the antibody is less variable between each antibody and is responsible for 
effector function of the antibody and for inducing a specific host clearance mechanism 
(Sondermann 2016).  While there has been considerable growth in our understanding of 
antibodies and their Fab and Fc regions, much of the focus has been on the antigen 




  Once antibodies are generated, they clear influenza virus infections in multiple 
ways.  The first and most simple mechanism for clearance is neutralization.  In this 
mechanism, the influenza virion is neutralized as the high-affinity antibodies bind to the 
HA protein and prevent the infection of host cells.  In this clearance mechanism, the Fc 
region plays a lesser role as compared to the Fab region and simply having an antibody 
which prevents infection by blocking important pathogenic effects, prevents virus spread. 
Today, when determining if a vaccination is protective against influenza infection, 
neutralization is the most commonly assessed means of protection. A second mechanism 
is the complement system in which IgG2a (IgG3 in humans) and IgG2b (IgG1 in 
humans) antibodies can initiate the interaction between multiple complement proteins 
that ultimately work toward eliminating a foreign pathogen.  Once initiated, this process 
leads to opsonophagocytosis, programmed killing of the infected cell or microbe, and/or 
recruitment of inflammatory cells (Stoermer 11).  The third mechanism of clearance is 
opsonization which is also referred to as antibody-dependent cellular phagocytosis 
(ADCP) in which antibodies use their Fab region to bind to the antigen, and the Fc 
portion of the antibody binds to Fc receptors prevalent through the immune system.  
Following Fc-Fc receptor interaction, phagocytic cells dispose of these viruses through 
opsonophagocytosis. The final mechanism of clearance of influenza virus is through 
antibody-dependent cell-mediated cytotoxicity (ADCC) in which the Fab region of an 
antibody binds to the HA proteins that are expressed on the surface of infected cells as 
part of the infection cycle.  The Fc region of these antibodies is then recognized by the Fc 




factors that lead to the death of the cell, ultimately preventing the production of further 
viral pathogens (Figure 1).  
 Historically, much of the focus of antibody research has been on the Fab region of 
antibodies; however, it is known that the Fc – Fc receptor interactions play an important 
role in effective antibody clearance of viral infections as well.  There are four well-
established Fc receptors, three that activate immune responses and one that inhibits 
immune responses (Sondermann 2016).  The activating Fc receptors are FcγRI, Fc𝛾RIII 
(Fc𝛾RIIA in humans), and Fc𝛾RIV (Fc𝛾RIIIA in humans) while the inhibitory receptor is 
Fc𝛾RIIB. When activated, each of the activating Fc receptors generates an intracellular 
signaling cascade modulated through the phosphorylation of immunoreceptor tyrosine-
based activation motifs (ITAM’s) which can lead to ADCP, ADCC and/or inflammation 
generated from the release of cytokines from immune cells.  The activating receptors are 
closely related, with key differences in both the binding affinity and the specificity with 
which antibodies react with each receptor.  This allows the immune response for the host 
to be diverse and to respond to many different pathogens.  FcγRI has the highest binding 
affinity for IgG2a; however, its binding affinity is so high the receptors are able to bind 
monomeric IgG2a at the same efficiency as newly formed immune complexes, so bound 
antibody would only have limited access to these receptors (Nimmerjahn 2006).  FcγRIII 
has a lower binding affinity, but has broad isotype binding patterns.  FcγRIV has an 
intermediate binding affinity for IgG2a compared to FcγRI and FcγRIII and, but like 
FcγRI, mostly binds IgG2a.  Due to a lower binding affinity than FcγRI, FcγRIV is 
unable to bind monomeric IgG2a, allowing more access to receptors for immune 




Fc receptor, FcγRIIB, prevents the activation of effector functions of the immune system 
by the phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) 
which recruit phosphatases that balance the activating pathways from FcγRI, FcγRIII, 
and FcγRIV (Wang 2017).  It is known that Fc receptor activation occurs when the 
incoming activating signal overrides the inhibitory signal from Fc𝛾RIIB.  However, it is 
not entirely understood how the mechanism in which Fc receptors respond to influenza 
on macrophages induces opsonophagocytosis.   
 
Section 5: Nanotechnology 
 Nanotechnology is a rapidly developing tool that is showing great potential to be 
used both in medical treatment and research.  Silica nanoparticles function as a stable 
particle that can be used for diagnostic purposes without reacting with the environment in 
many situations.  Additionally, the surface of silica nanoparticles can be easily modified 
using different alkoxysilanes and halosilanes, allowing proteins and other 
macromolecules to attach to the nanoparticle. (Liberman 2014).  Modified nanoparticles 
can then be used to study many in vivo reactions in isolation including the mechanism of 
antibody binding to pathogen and the host immune response induced after binding 
occures.  Protein attached to the nanoparticle can model surface proteins of bacteria or 
viruses and serve as an indicator of Fab binding effectiveness.  Further, when coupled 
with a cell that expresses Fc receptors that interact with the Fc region of the antibody, 
such as a macrophage, the function of the Fc region of the antibody can be tested.  Using 
this approach, one can evaluate the functional contribution of the entire antibody, rather 




virus with silica nanoparticles coated with protein, nanotechnology allows there to be 
greater safety when handling potentially dangerous pathogens. 
Section 6: Therapeutic Antibodies 
	
 The therapeutic antibody industry is rapidly growing, with a market of over 60 
billion dollars (Wang 2017).  Therapeutic antibodies are used in a wide variety of 
applications including treatment of cancer, autoimmune diseases, and infectious diseases.  
Specific interest in therapeutic antibodies to treat infectious diseases is growing as 
animals have been genetically modified to generate antibodies that are either human or 
human-like (Sano 2013, Beigel 2018). Specifically, there are multiple monoclonal 
antibody products that have been generated and tested for their effectiveness in 
preventing influenza infection (Salazar 2017).  Antibodies have been generated to interact 
with either the conserved regions of the HA protein or a different protein, M2e, which is 
present both on the surface of the influenza virus and on the surface of infected cells.  
Monoclonal antibodies are generated by isolating a B cell, which is known to secrete 
desirable influenza antibodies, fusing the B cell with an immortal cell, culturing this 
hybridoma B cell line, and generating a stock of antibody protein (National Research 
Council, 1999)).  Monoclonal antibody production is highly effective at generating 
antibodies that have a specific mechanism; however, this method does not mirror the 
mechanism in which host immune systems typically generate antibodies as a part of the 
immune response.   
 A second type of therapeutic antibody that can be produced is polyclonal in 
nature, and they are created by injecting animals with antigen and adjuvant, collecting 




2005).  By generating a therapeutic antibody in this fashion, it is possible to generate a 
wide variety of antibodies with different Fab regions that recognize the pathogen of 
interest, and a range of Fc expression that together more accurately simulates an immune 
response against an infection.  These antibodies are more difficult to characterize than 
monoclonal antibodies, but they more closely mirror the variety of effector functions that 














Figure 1: Antibodies generate multiple effector functions they can a) neutralize 
interaction between pathogen and host cells b) initiate complement which leads to cell 
lysis c) interact with Fc receptor on effector cells which leads to the release of cytokines 
and toxic granules d) interact with Fc receptors on phagocytic cells leading to antibody-





 Materials and Methods 
	
Section 1: Nanoparticle Synthesis 
 Two methods were used to prepare the silica nanoparticles used for the 
opsonophagocytosis assay.  The first method utilized magnetic stirring of the solution to 
ensure dispersion of reactants and was adapted from a known protocol from Dr. Sereda’s 
lab group (Rashwan, unpublished data). First, 20 ml of distilled water (1.10 mol) and 20 
ml of absolute ethanol (Pharmco-Aaper .26 mol) was added to a 100 ml round bottom 
flask and stirred using a magnetic stir bar for 15 minutes to ensure dispersion.  Then 4 ml 
tetraethyl orthosilicate (ACROS Organics 0.018 mol) was added, and the solution was 
stirred for an additional 20 minutes. Finally, 4 ml of 28% ammonium hydroxide (Fischer 
Scientific 0.102 mol) was added.  As silica nanoparticles form, and the condensation 
reaction proceeds, the solution should turn a blueish tint followed by the formation of a 
milky white precipitate.  Once the color of the solution visibly changed, the reaction was 
allowed to progress under gentle stirring for either 30 or 60 minutes.  Upon completion of 
this reaction, the solution was added to a 50 ml falcon tube and was centrifuged for 30 
minutes at 4,000 rpm or until the supernatant was clear with no turbidity.  The 
supernatant was then discarded, and the pellet was resuspended in 10 ml of absolute 
ethanol, and the wash procedure was repeated three additional times. Following the last 
wash procedure, the pellet was suspended in 15 ml of absolute ethanol and stored in 
refrigeration at 4 degrees Celsius. The nanoparticles were then measured using 




 The second method utilized a sonication bath to ensure dispersion of reagents 
according to previously determined methods (Roa, 2005).  First, 17 ml of distilled water  
and 16 ml of absolute ethanol were added to a 100 ml round bottom flask, which was 
added to a sonication bath.  After 10 min, 1 ml TEOS (0.0045 mol) was added, and the 
solution was sonicated for 10 min to ensure dispersion.  After 10 minutes, 37 mL of 30% 
ammonium hydroxide (0.94 mol) was added dropwise, and then the solution was allowed 
to react for 60 minutes with sonication.  Following this reaction, the same wash protocol 
was used to prepare the silica nanoparticles for storage and characterization.   
The following day, an amine group was added to the surface of the silica 
nanoparticles.  7.5 ml of the nanoparticle solution from the previous step was centrifuged 
for 10 minutes at 4,000 rpm or until the supernatant was clear.  The pellet was then 
resuspended in 15 ml of absolute ethanol.  The unfunctionalized nanoparticles were then 
added to a 100 ml round bottom flask along with 150 𝜇L of (3-aminopropyl) 
triethoxysilane (APTES, 0.00064 mol) and 28% ammonium hydroxide (0.0064 mol).  
The resulting solution was then stirred overnight at room temperature.  The next morning, 
the solution was centrifuged and spun at 4,000 rpm for 10 minutes or until the 
supernatant was clear.  This pellet was then resuspended in 10 ml of absolute ethanol, and 
the wash procedure was repeated three additional times.  Following the last wash, the 
pellet was resuspended in 15 ml of absolute ethanol for storage at 4 degrees Celsius.  
 To determine yield in the nanoparticle synthesis protocol, the aminated 
nanoparticle solution was added to a plastic weigh tray and allowed to dry overnight.  
The following day, or once all the ethanol had evaporated and the particles were entirely 




this step, the nanoparticles were resuspended in absolute ethanol for storage at a 
concentration of 20 mg/ml.   
 
Section 2: Nanoparticle Dye Conjugation 
 15.78 mg (798 𝜇L from 20 mg/ml stored solution) of previously prepared 
aminated nanoparticles were centrifuged at 14,000 rpm for 1.5 minutes.  The supernatant 
was discarded, and the aminated nanoparticle pellet was resuspended in 798 𝜇L of .1M 
sodium bicarbonate (Thermo Fisher Scientific pHrodo dye kit). The suspension was 
centrifuged at 14,000 rpm for 1.5 minutes, and the process was repeated once more.  
1 mg of dried pHrodo Red SE from the pHrodo Red Phagocytosis Particle 
Labeling Kit for Flow Cytometry (Thermo Fisher Scientific A10026), was suspended in 
150 𝜇L of dimethyl sulfoxide (DMSO Thermo Fisher Scientific pHrodo dye Kit). 50	𝜇L 
of the pHrodo dye stock solution was then diluted in 610 𝜇L forming a final 
concentration of .5 mg/ml. The 660 𝜇L of phrodo dye was used to resuspend the 
aminated nanoparticles pellet. The solution was sonicated for 30 seconds using a 
sonication bath to ensure adequate dispersion.  The mixture was then wrapped in tin foil 
and allowed to react with shaking overnight.  The following morning the solution was 
centrifuged at 14,000 rpm for 1 minute.  50 𝜇L of the supernatant was added to a 96 well 
plate, and the rest of the supernatant was saved for future experiments, and the pellet was 
resuspended in the wash buffer provided in the pHrodo dye kit.  This procedure was 
repeated 3 times with 50 𝜇L of subsequent supernatants added to the next wells on the 96 
well plate.  The remainder of the supernatant from each wash was discarded.  Following 




(.025 mol, Thermo Fischer Scientific) and centrifuged at 14,000 rpm for 1 minute.  50 𝜇L 
of the supernatant was added to the 96 well plate, and the remainder was discarded. The 
wash process was then repeated once more.  The pellet was resuspended in 1 mL of wash 
buffer, centrifuged at 14,000 rpm and 50 𝜇L was added to the 96 well plate, and the 
particles were suspended in 798 𝜇L of Buffer B.  50 𝜇L of the nanoparticle slurry was 
then added to the 96 well plate and the remaining 748 𝜇L were stored in refrigeration at 4 
degrees Celsius.  
 The 96 well plate was then examined under a UV transiluminator to verify 
fluorescence in the nanoparticle slurry well in addition to the subsequent loss of 
fluorescence in supernatant wells. 
 
Section 3: Protein Conjugation 
 100 𝜇g of influenza HA protein (Sinobiological) was suspended in 400 𝜇L of 
sterile PBS to form a .25 mg/ml concentration of protein.  748 𝜇𝐿 of phrodo conjugated 
nanoparticles (from the previous step) were centrifuged at 14,000 rpm for one minute, 
and the supernatant was discarded. The nanoparticle pellet was then resuspended in the 
protein solution.   This mixture was wrapped in tinfoil and allowed to react overnight 
with shaking. The following day the nanoparticles were centrifuged at 14,000 rpm for 1 
minute, and 25 𝜇L was added to a 96 well plate.  The remainder of the supernatant was 
discarded, and the procedure was repeated three more times.  Following the last wash, the 
solution was suspended in 789 𝜇L of PBS, then 25 𝜇L of the nanoparticle slurry was 
added to the 96 well plate, and the remainder of the solution was stored in refrigeration at 




decreasing protein concentration in subsequent washes as well as the presence of protein 
on the nanoparticle slurry. Each mg of nanoparticles is estimated to be conjugated 
nanoparticles having a coating of surface protein of 6.34 𝜇𝑔 which exceeds levels of 
protein which have previously been established in the Huber lab as the requirement in 
order to observe uptake in macrophage cells. 
 
Section 4: Tissue Culture  
 L929 cells were cultured in 75 mL tissue culture treated flasks using a media 
composed of 450 ml of Dulbecco’s Modified Eagle’s medium (DMEM) with 4.5 g/L 
glucose, L- glutamine and sodium pyruvate (Thermo Fisher Scientific), 50 mL heat-
inactivated fetal bovine serum (FBS, Atlanta Biologicals), and 5 mL pen-strep (Thermo 
Fisher Scientific).  Passaging of the L929 cells was done every three days or when the 
cells reached confluency.  First, the existing growth media was discarded, and the cells 
were rinsed using 10 mL of PBS.  Following the rinse, 10 mL of L929 growth media was 
added to the flask, the cells were scraped off the bottom of the flask, and the suspension 
of cells and growth media was centrifuged for 3 minutes at 1,500 rpm.  The supernatant 
was discarded, and the cell pellet was resuspended in 10 mL of fresh growth media. 1 mL 
of the cell solution was added to a new 75 mL tissue culture treated flask, and 19 mL of 
new growth media was added.   
L929 cells were used to produce colony stimulating factor 1 (CSF1) to stimulate 
macrophage differentiation.  Following the above passaging procedure, 2 mL of L929 
cells was added to 48 mL of L929 growth media in a 150 mL tissue culture treated flask.  




cultured for an additional 72 hours and then the L-cell conditioned media was aliquoted 
into 25 mL increments and stored below freezing until needed for the making mouse fetal 
liver macrophage media.   
 Mouse fetal liver macrophage cells (FLM) were cultured in 75 mL suspension 
culture flasks (Olympus Plastics) with growth media composed of 150 mL L-Cell 
conditioned media, 100 mL heat-inactivated FBS, 250 mL DMEM with 4.5 g/L glucose, 
L- glutamine and sodium pyruvate, and 5 mL pen-strep.  FLM cells were cultured every 
three days or once the cells reached confluency. The existing growth media was 
discarded, and the cells were then rinsed with 10 mL PBS. 10 mL FLM growth media 
was then added and cells were scrapped from the flask. The cell solution was centrifuged 
at 1,500 rpm for 3 minutes.  The supernatant was discarded and the cell pellet was 
resuspended in 10 mL of growth media. 1 mL of the FLM cell solution was then added to 
19 mL of FLM growth media in a 75 mL suspension culture flask.  
 
Section 5: Nanoparticle Opsonophagocytosis Assay 
 To develop the nanoparticle opsonophagocytosis assay we used macrophage cells 
that are known to express Fc𝛾 receptors.  Specifically, fetal liver macrophage (Review 
with Dr. Huber for specifics) cells from mice were used to monitor uptake.  20,000 FLM 
cells were added to two wells of a black 96 well plate with a clear bottom (Thermo 
Fischer Scientific) and were allowed to culture overnight.  The next day, 1 𝜇L of protein 
conjugated nanoparticles (20 mg/ml) was added to 10 𝜇L therapeutic antibody (1 mg/ml) 
to function as an experimental group and 1 𝜇L of protein conjugated nanoparticles was 




then sonicated using a sonication probe for 5 seconds at 10% power to ensure dispersion.  
Both conditions allowed to mix with shaking for 1 hour. The total volume of each test 
condition was then brought up to 200 𝜇L by adding 189 𝜇L of Dulbecco’s Modified 
Eagle’s medium.  Preexisting growth media was then removed from the FLM cells and 
was replaced with the nanoparticle solution and allowed to incubate for 1 hour.  
Following the incubation, the nanoparticle solution was removed, and the cells were 
washed gently two times with 200 𝜇L of PBS.  
The cells were fixed by adding 80 𝜇L of 2% paraformaldehyde for 10 minutes.  
The paraformaldehyde was then removed, and the cells were washed 3 additional times 
using 200 𝜇L of PBS.  The fixed cells were then stained using 80 𝜇L of a stock solution 
Wheat Germ Agglutinin Alexa Flour 488 (Thermo Fisher Scientific .14mg/1mL) and 80 
𝜇L of HCS Nuclear Mask Blue (Thermo Fisher Scientific .5 𝜇L of stock solution/1ml).  
The dye was allowed to react with the cells for 30 minutes, and the cells were washed 2 
additional times using 200 𝜇L PBS. Cells were then visualized using fluorescent 
microscopy.   
 





Chapter Three: Results 
	
 It was determined, using TEM microscopy, that the most efficient method of 
nanoparticle synthesis was by allowing the mixture of tetraethyl orthosilicate, ammonium 
hydroxide, distilled water, and absolute ethanol to react via stirring (rather than 
sonication) for thirty minutes (rather than 60 minutes) as it minimized the amount of 
ammonium hydroxide needed, used a less complicated reaction apparatus, and yielded 
particles that were of similar size compared to that of typical influenza virions. Results 
from transmission electron microscopy (Figure 2) were analyzed through ImageJ 
processing, and it was determined that the average diameter of each particle that was 
prepared via this method was 141.75 nm with a standard deviation of 23.81 nm.  If the 
solution was stirred for 60 minutes, the average nanoparticle size increased to 393.12 nm 
with a standard deviation of 20.16 nm.  When sonication was used instead of stirring the 
nanoparticle diameter was found to be an average of 237.31 nm with a standard deviation 
of 33.96 nm.  It is known that an average influenza virion is between 80 – 120 
nanometers in diameter (Noda 2011), so the first method yielded the particles that most 
closely mirrored this size.  It was concluded that it was vital that the procedures were 
completed entirely, or the tetraethyl orthosilicate continued to react forming linkages 
between particles which lead to aggregation of the particles which impeded the 
effectiveness of the assay.  
 Another important variable that was optimized through experimentation was the 
concentration of nanoparticles used per uptake assay. It was found that if too many 
nanoparticles were used, there were greater amounts of background fluorescence in the 




lack of a negative control. An optimal level of protein conjugated nanoparticle per 20,000 
cells was 20 𝜇g or 1 𝜇L of the 20 mg/ml stored stock of nanoparticles was established 
(Figure 3).  
 Therapeutic antibody concentration was also established to impact the rate of 
opsonophagocytosis.  In initial experiments, an antibody concentration of 10 mg/ml was 
used, and uptake by macrophages was observed at a lower level.  We hypothesize that 
this is the result of high levels of neutralization preventing opsonization.  Hemagglutinin 
plays an essential role in the attachment of influenza to the cellular membrane via binding 
with sialic acid (Russell 2008).  As a result, to effectively initiate effector function of host 
cells there must be an interaction between both hemagglutinin of the influenza virus with 
a sialic acid of the host cell, as well as Fc-Fc𝛾R interaction (Leon 2016).  As the 
therapeutic antibody used in these assays was polyclonal in nature, it is expected there are 
antibodies which are react with different HA epitopes. It is suspected that the polyclonal 
sample contains antibodies which neutralize HA by preventing interaction with host cell 
sialic acid as well as antibodies which do not lead to neutralization.  In high concentration 
of antibody product, it is expected that a higher percentage of HA is neutralized, 
preventing Fc-Fc𝛾R interaction and phagocytosis.  Once the antibody was diluted in PBS 
to a concentration of 1 mg/ml, it was found that the rate of phagocytosis increased 
drastically (Figure 4).  It is hypothesized that at this dilution there is an antibody binding 
to some HA proteins on the surface of the nanoparticles; however, there is still HA 
available to bind with sialic acid on the macrophage cells. 
 Finally, it was determined that there was a quantifiable difference in the uptake in 




nanoparticles as compared to when no antibodies were added (Figure 5).  By adding 
therapeutic antibodies to coat the nanoparticles, the increased rate of opsonophagocytosis 
in vaccinated individuals is simulated. These results were established using a 
hemagglutinin protein variant from the 2009 pandemic (A/California/07/2009 
Sinobiological).  Each assay was analyzed using fluorescent microscopy at 5X, 10X, 
20X, and 40X magnification. An increase in phagocytosis of nanoparticles was noticed at 
each magnification.  Following image capture, the number of nanoparticle aggregates 
was counted using ImageJ.  Images generated from assays at 10X magnification, in 
which antibody was added, averaged 271.85 nanoparticles, while PBS control images 
averaged 58.6 nanoparticle aggregates.  These results were found to have a significant 







Figure 2: TEM images of Silica Nanoparticles 
a) Stirring method with 30 minute reaction time. Average Diameter = 141.75  
b) Stirring method with 60 minute reaction time. Average Diameter = 393.12  
c) Sonication method with 60 minute reaction time. Average Diameter = 237.21.  







Figure 3: Effect of Nanoparticle Concentration in Uptake Assay 
a) 20 𝜇g of nanoparticle coated with 10 ul of 1 mg/ml therapeutic antibody  
b) 20 𝜇g of nanoparticle coated with PBS as a negative control  
c) 80 𝜇g of nanoparticle coated with 10 ul 1mg/ml of therapeutic antibody  
d) 80 𝜇g of nanoparticle coated with PBS as a negative control.   
It was established that 20 𝜇g of protein conjugated nanoparticle is optimal concentration 
as background fluorescence is minimized while maintaining a concentration which allows 

















Figure 4: Effect of Antibody Concentration on Uptake in Macrophage Cells 
a) Therapeutic antibody with concentration of 1 mg/ml was used  
b) Therapeutic antibody concentration of 5 mg/ml was used  
c) Therapeutic antibody concentration of 10 mg/ml was used  
It was established that the rate of phagocytosis was increased when a more dilute 







Figure 5: Presence of Antibody Effect on Nanoparticle Uptake   
Fluorescent microscopy imaging of nanoparticle uptake at 20X magnification. Images a) 
and b) had PBS added as a negative control, images c) and d) show increased uptake as 






Figure 6: Average of Number of Nanoparticle Aggregates Observed per Image.   
Samples coated in therapeutic antibody had an average of 272.85 nanoparticle aggregates 
with a standard deviation of 56.34.  Negative control samples showed an average of 58.6 
aggregates per image with a standard deviation of 20.07.  Error bars are additionally 
shown at a 95% confidence interval.  Results are statistically significant with a P value of 





Chapter Four: Discussion 
	
 For the optimization of this assay, hyperimmunized polyclonal antibodies 
generated for a therapeutic purpose were used.  Using a consistent source of antibodies, 
we were able to control the reaction conditions so that they were repeatable in 
independent trials.  A standard of using 10 𝜇𝑔 of therapeutic antibody (10 𝜇𝐿 of antibody 
at a concentration of 1 mg/mL) was used and was held consistent between trials as 
compared to the alternative of using sera samples within which antibody concentration 
and type may vary sample to sample.  However, based on our findings we are confident 
that this assay could also be used to verify the effector function of different monoclonal 
and polyclonal antibody functions as new antibodies are generated and characterized for 
their therapeutic functions.  Specifically, comparisons could be made based on the ability 
of different antibodies to elicit opsonophagocytosis, as quantified by the presence of 
fluorescent particles within macrophages.   
 Here we demonstrate that a cell-based assay can be used to determine Fc receptor-
mediated opsonophagocytosis as an inexpensive experimental model to verify that 
antibody populations, either monoclonal or polyclonal, can effectively induce 
phagocytosis in macrophages before expensive animal challenge models and human 
clinical trials are designed. Additionally, by understanding which region of the antibody 
contributes to protection allows us to ensure that antibodies with the desired effector 
function are being used to bridge the interaction between both the pathogen and the host 
immune system (Forthal 2014).  To mount an effective immune response against 
influenza, it is known that having antibodies which neutralize and activate phagocytosis 




response (Huber 2001, Huber 2006).  Furthermore, a nanoparticle uptake assay can also 
be used as a quality control mechanism to compare preparations of therapeutic antibody 
and verify that the effector function of remains consistent between samples of antibody 
that may be generated across a period of time.   
 While it is known that phagocytosis is needed to effectively protect a host against 
an influenza virus infection, it is still unknown which Fc receptor on macrophage cells 
has the most significant impact on opsonophagocytosis of the influenza virus.   Our goal 
is to design a nanoparticle assay that is able to consistently evaluate the interaction of the 
Fc region of the antibody with host cells, and this work is a step toward achieving that 
goal.  Once we have the antigen and antibody aspect of the assay optimized, it will be 
possible to determine which Fc receptor plays the most significant role in influenza virus 
clearance.  Fc receptor knockout cells have been generated from FLM cells using 
CRISPR/Cas9 system and can be used directly in this assay to determine the mechanism 
of interaction between influenza and the adaptive immune system.  
It is anticipated that there are would be multiple unique effects of removing 
different elements of the Fc receptor system.  Firstly, it is expected that if the entire Fc 
receptor common gamma chain (FcR𝛾) were inactivated, there would be widespread 
deficiencies in antibody mediated uptake (Brandsma 2009). FcR𝛾 plays an essential role 
in each of the three major activating Fc𝛾 receptors, and without the activation of these 
receptors, Fc𝛾RIIB would send inhibitory signals preventing an immune response in the 
presence of antibody.  If Fc𝛾RIIB was inactivated, it is known that there is increased 
immune activity, commonly to the extent in which autoimmunity develops, as even 




Finally, when considering the removal of an individual activating Fc receptor, it is 
expected that Fc𝛾RIV will have the most significant effect on the amount of immune 
response (Nimmerjahn 2006).  Sincc Fc𝛾RIV has an intermediate binding affinity, it can 
bind an increasing number of immune complexes as antibody concentration increases, 
while still possessing a greater binding affinity than Fc𝛾RIIB, allowing the activating 
signal to override the inhibitory signal.  
 An additional future step which may enhance our assay is to compare the 
differences between nanoparticles used in these experiments.  Currently, we synthesize 
nanoparticles with electrostatic attachment of HA. Another mechanism we have explored 
is generating nanoparticles with covalent attachment of HA.  Positive results have been 
generated using simple electrostatic interactions; however, it is hypothesized that once 
nanoparticle and HA concentration is optimized, covalently bound protein would be a 
more accurate and reliable measure of opsonophagocytosis. It is unknown which region 
of the protein is bound to the nanoparticle when electrostatic interactions are used, and it 
is possible that the antibody binding site of the protein may be bound to the surface of the 
nanoparticle which then prevents the Fab region of the antibody from binding to the 
protein.  If a procedure was optimized for covalent coupling, it would be possible to 
generate a consistent binding between the carboxyl group of the protein and the amino 
groups present on the surface of the silica nanoparticle. It is expected that this approach 
would provide more realistic results as the HA protein would be bound to the 
nanoparticle consistently in the stalk region and would be able to generate more uniform 




 The consistency and repeatability of our assay relies on the use of recombinant 
protein rather than the whole virus.  This is beneficial due to the ability to control protein 
expression on the nanoparticles and because it provides an opportunity for scientists to 
avoid potential risks of handling dangerous pathogens. This assay provides an 
opportunity for scientists to run diagnostic assays on a bench top without the use of 
infectious organisms.  With silica nanoparticles being easy to synthesize, and many types 
of recombinant protein available, it will be possible to evaluate antibody concentration of 
a serum sample in a short period of time without the requirement of the generation of a 
viral stock.  Once the protein-conjugated nanoparticles are synthesized, it would be a 
simple process to evaluate a sera sample against many different strains of influenza to 
determine which strains of influenza a person has generated antibodies against, and to 
what extent a vaccine generates protections against other strains of influenza.   
 By generating an assay that avoids the use of live virus, there are potential 
applications when considering viruses that pose great danger to scientists handling them 
such as Ebola, HIV, or avian influenza.  Similar methods could be used to attach surface 
proteins, and the assay could be used in an open-air clinical setting to determine if a 
patient had been exposed to a pathogen by determining if there was antibody present 
within a serum sample.   
 A nanoparticle uptake assay could be used as a model to determine other 
mechanisms of Fc mediated interactions outside of opsonophagocytosis to evaluate 
influenza immunity. Most influenza vaccines are evaluated for their ability to generate 
antibodies which cause neutralization in the host; however, it is known that neutralization 




Additionally, it has been found that antibodies that are deemed as non-neutralizing may 
have other effector functions within a host. One specific application of interest would be 
to analyze the activation of NK cells as the best way to generate an ADCC response. NK 
cells are known to also possess Fc receptors and clear virus-infected cells through ADCC.  
There are known ELISA procedures which recognize IFN-𝛾 and CD107a which are used 
as markers of cytotoxicity and indicate when NK cells are activated and ADCC is 
induced (Jegaskanda 2013). Specifically, the matrix-2 protein (M2) and the ectodomain 
region of the M2 protein (M2e) are of interest.  M2e only composes 1-10% of the surface 
area of the influenza virus as compared to HA (Bouvier 2008).  However, M2e is found 
in a much higher quantity on the surface of infected host cells and has been found to be a 
good marker to determine if host cells have been infected with influenza virus.  M2e is 
highly evolutionarily conserved, and there are few known variants amongst all influenza 
A viruses. Thus, vaccination against the M2e protein has been established as a potential 
mechanism to develop a more broadly protective vaccine.  As M2e is expressed more on 
the surface of host cells, it is important that antibodies generated because of M2e 
vaccination lead to a response that affects infected cells through ADCC or ADCP. 
Protein-conjugated silica nanoparticles could be generated to specifically monitor the 
effects of ADCC in response to M2e vaccination.  Nanoparticles could be synthesized in 
a similar manner to the HA nanoparticles that were used in this study. These M2e 
nanoparticles would be coated in wells of a plate, antibody samples generated from an 
animal vaccinated against M2e would be added, and cytokines generated in NK cells 
would be analyzed to determine the activation as a result of Fc receptor interaction.  




highly useful role in determining protection instead of purely the neutralization response 







Chapter Five: Conclusion and Summary 
	
 By developing our nanoparticle opsonophagocytosis assay, we have established 
that nanoparticles that are conjugated with HA protein can be used to evaluate 
interactions between antibodies and macrophage cells in a manner that mimics whole 
influenza virus.  Using silica nanoparticles, it is possible to validate both the Fc receptor 
interaction as well as the Fab binding toward a pathogen, which is an improvement on the 
current models used to determine protection, which only identify the Fab binding.  This 
model shows great promise toward generating a new diagnostic assay in which correlates 
of protection may be determined while considering the entire functionality of antibodies.  
By using silica nanoparticles, as compared to live virus, we have developed an assay that 
is simple and safe to set up, easy to perform, and has potential clinical significance in 
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